Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research

Key Points

• Zacks Research downgraded Gyre Therapeutics from “hold” to “strong sell,” while other firms have also issued negative ratings. Despite this, the overall analyst consensus remains “hold,” with a $17 target price.
• Gyre reported a quarterly loss of $0.12 per share, missing estimates by $0.06, although revenue of $29.11 million exceeded expectations. Analysts project a full-year loss of $0.61 per share.
• The stock opened at $7.15, with a market capitalization of about $797 million, while institutional investors and hedge funds own 23.99% of shares.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) was downgraded by Zacks Research from a "hold" rating to a "strong sell" rating in a research report issued on Tuesday,Zacks.com reports.

A number of other research firms also recently commented on GYRE. Weiss Ratings reiterated a "sell (d-)" rating on shares of Gyre Therapeutics in a report on Friday, August 7th. Wall Street Zen lowered Gyre Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $17.00.

Gyre Therapeutics Price Performance

NASDAQ:GYRE opened at $7.15 on Tuesday. The company's fifty day moving average price is $6.38 and its 200-day moving average price is $7.00. Gyre Therapeutics has a 1-year low of $5.44 and a 1-year high of $9.42. The firm has a market capitalization of $797.30 million, a P/E ratio of -34.05 and a beta of 1.92.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%. The firm had revenue of $29.11 million during the quarter, compared to analyst estimates of $26.49 million. Equities analysts anticipate that Gyre Therapeutics will post -0.61 EPS for the current fiscal year.

Institutional Trading of Gyre Therapeutics

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after acquiring an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock valued at $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock worth $54,000 after purchasing an additional 3,244 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Gyre Therapeutics during the 4th quarter worth $77,000. Finally, Wells Fargo & Company MN grew its stake in shares of Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company's stock worth $91,000 after purchasing an additional 7,361 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source